Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

UniQure gene therapy shows promising result in mid-stage trial

Gene therapy company UniQure NV said on Friday the company’s experimental treatment for hemophilia B increased the levels of a protein that helps in blood clotting after 12 weeks in a relatively small study.

Read More »

Prior dengue infection may protect against Zika: study

Prior infection with dengue, a mosquito-borne disease that infects nearly 400 million people a year, could reduce the risk of contracting Zika nearly by half, U.S. and Brazilian researchers reported.

Read More »

Sanofi Cuts 38 R&D Programs to Refocus on Cancer, Immunology, and Rare Diseases

Sanofi reportedly ended 38 R&D programs and is prioritizing oncology, immunology, rare disease and rare blood disorders.

Read More »

HiberCell Launches With $60.75 Million Series A to Target Dormant Metastatic Cancer Cells

New York City-based HiberCell launched with a $60.75 million Series A funding, led by ARCH Venture Partners.

Read More »

GSK Cuts Six Respiratory Assets as It Continues to Focus on Oncology Treatments

GlaxoSmithKline is significantly reshaping to focus on pharmaceuticals, particularly a renewed interest in oncology treatments. As a result, the company made some cuts to the product pipeline, including six in GSK’s 2018 year-end report.

Read More »

Most U.S. kids not meeting sleep, exercise and screen time targets

Just one in 20 U.S. children and teens gets the amount of sleep, exercise and screen time that doctors recommend for optimal health, a new study suggests.

Read More »

Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis

Eli Lilly and Company and Incyte Corporation announced that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with moderate to severe atopic dermatitis.

Read More »

Janssen and MeiraGTx Sign $440 Million Deal to Develop Gene Therapies for Eye Diseases

Janssen Pharmaceutical, a Johnson & Johnson company, inked a worldwide collaboration and license deal with MeiraGTx to develop, manufacture and commercialize a portfolio of drugs for inherited retinal diseases.

Read More »

Israel’s Accelerated Evolution Biotechnologies Claims a Cure for Cancer

Accelerated Evolution Biotechnologies’s claims to have found a cure for cancer are, appropriately, being met with global skepticism.

Read More »

Roche, AC Immune drop Alzheimer’s drug trials

Roche Holding and partner AC Immune called a halt to two late-stage studies of the companies’ crenezumab drug for early Alzheimer’s, the latest in a string of failures to find a treatment for the progressive brain disease.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom